Anupreet Kharbanda
Researcher
University of Arkansas for Medical Sciences
faculty
Research Areas
Links
Is this your profile? Verify and claim your profile
Biography and Research Information
OverviewAI-generated summary
Anupreet Kharbanda's research focuses on the discovery and development of novel therapeutic agents for cancer and other diseases. This work involves structure-based drug design and optimization, targeting specific molecular pathways implicated in disease progression. Publications include the identification of inhibitors for FLT3 and its mutants in acute myeloid leukemia, and N-trisubstituted pyrimidine derivatives as inhibitors of Type I RET and RET gatekeeper mutants.
Further research explores the potential of tocotrienols as an anti-breast cancer agent and the discovery of selective TGFβR1 inhibitors for immuno-oncology applications. Kharbanda also investigates novel non-kinase TGFβ pathway inhibitors and the destruction of DNA-binding proteins using programmable oligonucleotide PROTACs (O'PROTACs), targeting proteins like LEF1 and ERG. Collaborations include work with Yuet-Kin Leung, Brendan Frett, Phuc Tran, and Xiuqi Wang at the University of Arkansas for Medical Sciences.
Metrics
- h-index: 12
- Publications: 16
- Citations: 431
Selected Publications
- Revisiting Aurora Kinase B: A promising therapeutic target for cancer therapy (2023) DOI
- Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose (2022) DOI
- Tocotrienols as an Anti-Breast Cancer Agent (2021) DOI
- Destruction of DNA‐Binding Proteins by Programmable Oligonucleotide PROTAC (O'PROTAC): Effective Targeting of LEF1 and ERG (2021) DOI
- Discovery of imidazo[1,2-a]pyridine-thiophene derivatives as FLT3 and FLT3 mutants inhibitors for acute myeloid leukemia through structure-based optimization of an NEK2 inhibitor (2021) DOI
- Discovery of 4-aminoquinolines as highly selective TGFβR1 inhibitors with an attenuated MAP4K4 profile for potential applications in immuno-oncology (2021) DOI
- Discovery and biological evaluation of phthalazines as novel non-kinase TGFβ pathway inhibitors (2021) DOI
- Destruction of DNA-binding proteins by programmable O’PROTAC: Oligonucleotide-based PROTAC (2021) DOI
Collaborators
Researchers in the database who share publications
Similar Researchers
Based on overlapping research topics